Niagen Bioscience (NASDAQ:NAGE – Get Free Report) and Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.
Valuation and Earnings
This table compares Niagen Bioscience and Foghorn Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Niagen Bioscience | $129.42 million | 3.00 | $17.38 million | $0.20 | 24.25 |
| Foghorn Therapeutics | $30.91 million | 9.04 | -$74.28 million | ($1.17) | -4.07 |
Analyst Recommendations
This is a breakdown of recent recommendations for Niagen Bioscience and Foghorn Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 3 | 0 | 2.75 |
| Foghorn Therapeutics | 1 | 0 | 7 | 1 | 2.89 |
Niagen Bioscience presently has a consensus target price of $16.00, suggesting a potential upside of 229.90%. Foghorn Therapeutics has a consensus target price of $11.13, suggesting a potential upside of 133.72%. Given Niagen Bioscience’s higher possible upside, equities analysts plainly believe Niagen Bioscience is more favorable than Foghorn Therapeutics.
Profitability
This table compares Niagen Bioscience and Foghorn Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 13.43% | 21.10% | 14.92% |
| Foghorn Therapeutics | -240.33% | N/A | -33.46% |
Institutional & Insider Ownership
15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Niagen Bioscience has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 2.97, indicating that its stock price is 197% more volatile than the S&P 500.
Summary
Niagen Bioscience beats Foghorn Therapeutics on 9 of the 15 factors compared between the two stocks.
About Niagen Bioscience
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
About Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
